Third Time Lucky? Eli Lilly and Eisai Get Another Shot At English Funding For Alzheimer’s Drugs

 
• By Neena Brizmohun
  
Dementia and Parkinson's disease, ADHD, composition for head disease theme, space for text
Lilly and Eisai still need to convince NICE that their Alzheimer's disease drugs are cost effective (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Geography